Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health

McKesson

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

3 Stocks to Tap the Promising Dental Supplies Industry

EXTON, Pa., July 15, 2021 /PRNewswire/ --  West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2021 financial results before the market opens on Thursday, July 29, 2021, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Second-Quarter 2021 Conference Call

AbbVie

Abbott Labs

Caterpillar

Colgate-Palmolive

Lowe's

Oracle

Royal Bank of Canada

Watsco

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: July 13-26, 2021

Phibro Animal Health

ResMed

Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.

Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD

BellRing Brands Inc

Harrow Health Inc

Henry Schein

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market

National Vision Hlds

Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.

3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic

Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio

Accenture Plc

Applied Materials

Bank of New York Mellon

Blackrock Inc

Comcast

Cintas Corp

Expeditors International of Washington

General Dynamics

Home Depot

Hershey

Lockheed Martin

Mastercard

Northrop Grumman

Roper Technologies

Charles Schwab

T. Rowe Price Group

U.S. Bancorp

Visa

There are 21 stocks on my dividend growth watchlist for June 2021. The average 10-year dividend growth rate for these stocks is 15.67%.

Dividend Growth Stock Watchlist - June 2021

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical (WST).

Is West Pharmaceutical (WST) a Great Growth Stock?

West Pharmaceutical (WST) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love West Pharmaceutical (WST)

EXTON, Pa., May 25, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that management will present at the Jefferies Virtual Healthcare Conference at 2:30 PM ET on Tuesday, June 1, 2021.  A live broadcast of the event will be available at the Company's website, www.westpharma.com, in the "Investors" section under "Events".

West Announces Participation in Upcoming Investor Conference

West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Growth Investors Shouldn't Overlook West Pharmaceutical (WST)

Daqo New Energy

Louisiana-Pacific

Nucor

PulteGroup

For a prudent investor, a safe strategy of choosing stocks should include search for stocks that bear a low leverage. You may buy DQ, LPX, NUE, WST and PHM.

5 Stocks With Low Debt-to-Equity Ratio to Boost Your Portfolio

EXTON, Pa., May 5, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a third-quarter 2021 dividend of $0.17 per share. The dividend will be paid on August 4, 2021, to shareholders of record as of July 21, 2021.

West Announces Third-Quarter Dividend and Participation in Upcoming Investor Conference

Apple

Generac Holdings

Alphabet

MKS Instruments

This may be a good time to invest in growth stocks.

These 5 Growth Stocks Are Worth a Closer Look

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q1 2021 Results - Earnings Call Transcript

Shares of West Pharmaceutical Servs (NYSE:WST) fell 0.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 102.97% year over year to $2.05, which beat the estimate of $1.43.

West Pharmaceutical: Q1 Earnings Insights

EXTON, Pa., April 29, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance. First-Quarter 2021 Summary (comparisons to prior-year period) Net sales of $670.7 million grew 36.5%; organic sales growth was 31.1%.

West Announces First-Quarter 2021 Results

Best Buy

iShares MSCI USA ESG Optimized ETF

Vanguard ESG US Stock ETF

NVIDIA

SPDR S&P 500 Fossil Fuel Reserves Free ETF

The stocks of the future may also be good for your investment returns in the present.

Are You Overlooking These Stocks of the Future?

EXTON, Pa., April 15, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2021 financial results before the market opens on Thursday, April 29, 2021, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host First-Quarter 2021 Conference Call

New York, New York--(Newsfile Corp. - March 31, 2021) - Levi & Korsinsky announces it has commenced an investigation of West Pharmaceutical Services, Inc. (NYSE: WST) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/west-pharmaceutical-services-inc-information-request-form\or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of West Pharmaceutical Services, Inc. (WST)

3 Stocks to Capitalize on Promising Dental Supplies Industry

EMCOR Group

Microsoft

Texas Instruments

ESG investing will continue its northward momentum and this calls for investing in NVIDIA (NVDA), Microsoft (MSFT), EMCOR (EME), West Pharma (WST) and Texas Instruments (TXN)

Steady Rise in ESG Investing to Boost These 5 Stocks

EXTON, Pa., Feb. 24, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2021 dividend of $0.17 per share. The...

West Announces Second-Quarter 2021 Dividend

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q4 2020 Results - Earnings Call Transcript

News for West Pharmaceutical Services Stock (WST)